← brief for 2026-08-11 · Slowing decline

A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

Trial No results yet Not peer reviewed

Key takeaways

This 5-year trial tests orforglipron, a GLP-1 drug taken as a pill, against a placebo in adults with heart disease and/or chronic kidney disease. It measures whether the drug prevents heart attacks, strokes, and related events. It is just starting, so there are no results yet.

Who did this work

Run by Eli Lilly and Company. Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) (Eli Lilly and Company)
Sites: Instituto de Investigaciones Clínicas Bahia Blanca · CONEXA Investigacion Clinica S.A. · Buenos Aires Macula S.A · CIPREC · Instituto Médico Especializado (IME) · Cicemo Srl

Source

Trial · ClinicalTrials.gov, CKD recruiting · 2026-08-06
https://clinicaltrials.gov/study/NCT07241390